GlassScriptPhysician profile
Joy C Sawicki
NPI 1740715531
$4,756.23
in general payments reported to CMS, 2019-2025
25 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 96% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
See the full distribution for Critical Care Medicine (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $336 · 2023: $798 · 2024: $2,137 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429 · Travel and Lodging: $722 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,429.01 |
| Travel and Lodging | $722.02 |
| Education | $119.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,308.57 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $1,157.80 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Harmony Biosciences LLC | $530.44 | 2023-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $290.93 | 2023-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $255.02 | 2021-2025 | |
| Axsome Therapeutics, INC. | $241.40 | 2024-2025 | Sunosi |
| Astrazeneca Pharmaceuticals LP | $141.51 | 2022-2025 | Fasenra, Tezspire, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.01 | 2021-2024 | Ofev, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $111.74 | 2022-2024 | Dupixent |
| Amgen INC. | $95.50 | 2022-2025 | Tezspire |
| Verona Pharma, INC. | $73.96 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $62.65 | 2022-2024 | Yupelri |
| Optinose US, INC. | $56.21 | 2023-2024 | |
| Blueprint Medicines Corporation | $37.02 | 2023 | Ayvakit |
| Lilly USA, LLC | $34.20 | 2025 | Mounjaro, Zepbound |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $33.03 | 2025 | Arikayce |
| Electromed, INC. | $31.24 | 2025 | Smartvest |
| Abbvie INC. | $29.84 | 2022 | |
| Genzyme Corporation | $22.50 | 2023 | |
| Csl Behring | $21.12 | 2023 | Hizentra |
| Biogen, INC. | $19.41 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.67 | 2025 | Eohilia |
| Philips North America LLC | $16.50 | 2025 | Vest Therapy Und |
| Kaleo, INC. | $14.87 | 2022 | |
| Merck Sharp & Dohme LLC | $14.09 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Sawicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.